Xencor, Inc. (NASDAQ:XNCR)‘s stock had its “buy” rating reaffirmed by equities researchers at Piper Jaffray Companies in a research report issued to clients and investors on Sunday. They presently have a $35.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 66.43% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Canaccord Genuity restated a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. BidaskClub lowered Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $30.25.

Shares of Xencor (XNCR) traded up $1.07 during midday trading on Friday, reaching $21.03. The company had a trading volume of 146,300 shares, compared to its average volume of 215,876. Xencor has a 52-week low of $18.55 and a 52-week high of $29.38.

COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (XNCR) Earns Buy Rating from Piper Jaffray Companies” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.watchlistnews.com/xencor-inc-xncr-earns-buy-rating-from-piper-jaffray-companies/1700413.html.

In other Xencor news, major shareholder John S. Stafford III bought 50,000 shares of Xencor stock in a transaction dated Thursday, November 2nd. The stock was acquired at an average cost of $19.58 per share, with a total value of $979,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III bought 13,700 shares of Xencor stock in a transaction dated Tuesday, October 31st. The shares were acquired at an average cost of $19.81 per share, with a total value of $271,397.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 427,209 shares of company stock valued at $8,537,686. Corporate insiders own 4.14% of the company’s stock.

Several hedge funds have recently made changes to their positions in XNCR. FMR LLC raised its stake in shares of Xencor by 77.7% during the 2nd quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after buying an additional 2,924,510 shares during the period. State Street Corp raised its stake in Xencor by 17.5% in the 1st quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after purchasing an additional 148,136 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Xencor by 57.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock valued at $6,863,000 after purchasing an additional 104,638 shares during the last quarter. Artal Group S.A. acquired a new position in Xencor in the 3rd quarter valued at $2,292,000. Finally, JPMorgan Chase & Co. raised its stake in Xencor by 48.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after purchasing an additional 93,975 shares during the last quarter. 76.70% of the stock is owned by institutional investors and hedge funds.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.